Get the Stockscreener App
11.67
1.13%
0.13
After Hours:
11.55
-0.12
-1.03%
CorMedix Inc stock is traded at $11.67, with a volume of 1.34M.
It is up +1.13% in the last 24 hours and down -5.28% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$11.54
Open:
$11.5
24h Volume:
1.34M
Relative Volume:
0.67
Market Cap:
$791.51M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-12.68
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
+1.48%
1M Performance:
-5.28%
6M Performance:
+13.63%
1Y Performance:
+154.80%
1-Day Range:
$11.50
$11.87
1-Week Range:
$11.38
$12.07
52-Week Range:
$3.61
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
11.67 | 858.91M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
How does CorMedix Inc. generate profit in a changing economyExpert Picks Report For Fast Growth - jammulinksnews.com
What are the technical indicators suggesting about CorMedix Inc.Best Dividend Report With High Returns - jammulinksnews.com
Is CorMedix Inc. stock overvalued or undervaluedRetirement Planning Tracker To Watch Now - jammulinksnews.com
Is CorMedix Inc. Forming a Bottom PatternProfit Focused Stock Screener Results Released - metal.it
CorMedix Inc. recovery potential after sell offBuy Alerts With Low Risk Confirmation Noted - metal.it
Published on: 2025-07-29 17:35:04 - metal.it
Live Scanner Shows Breakout on CorMedix Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How did CRMD's Q4 earnings surprise impact investor confidence? - AInvest
Reversal Confirmed CorMedix Inc. Stock Rallies Above MAWeekly Stock Watch With Growth Focus Expanded - metal.it
CorMedix Inc. Attempts Reversal From Key SupportInvestment Strategy With Predictable Gains Outlined - metal.it
What is the dividend policy of CorMedix Inc. stockAI Powered Updates From AI Tools - jammulinksnews.com
Why CorMedix Inc. stock attracts strong analyst attentionSmart Return Focused Trading - metal.it
Should I hold or sell CorMedix Inc. stock in 2025Massive profits - jammulinksnews.com
What makes CorMedix Inc. stock price move sharplyMaximize returns with strategic stock selection - jammulinksnews.com
Is it the right time to buy CorMedix Inc. stockPhenomenal trading returns - jammulinksnews.com
When is CorMedix Inc. stock expected to show significant growthHigh-impact investment strategies - jammulinksnews.com
What is CorMedix Inc. company’s growth strategyConsistently outstanding ROI - jammulinksnews.com
What catalysts could drive CorMedix Inc. stock higher in 2025Get real-time alerts on high-potential stocks - jammulinksnews.com
CorMedix slides after pricing $85M stock offering - MSN
Does CorMedix Inc. stock perform well during market downturnsInvest smarter with expert stock recommendations - jammulinksnews.com
CorMedix Inc. Stock Analysis and ForecastFree Consultation - PrintWeekIndia
What drives CorMedix Inc. stock priceExceptional earning trajectories - Autocar Professional
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating, Announces Target Price $11.5 - 富途牛牛
What makes CorMedix Inc. stock attractive to long term investorsHigh-profit trading signals - jammulinksnews.com
What analysts say about CorMedix Inc. stockFree Predictions - PrintWeekIndia
Is CorMedix Inc. a good long term investmentRemarkably fast returns - PrintWeekIndia
Judge Scraps Opinion After Lawyer Flags Made-Up Quotes (Correct) - Bloomberg Law News
CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock? - MSN
Federal judge withdraws opinion after lawyer points out fake quotes, misstated case outcomes - ABA Journal
CorMedix’s DEFENCATH® Study: A Potential Game-Changer in Infection Prevention - MSN
NJ Fed. Judge Pulls Opinion Flagged With Nonexistent Quotes - Law360
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):